GIMEMA ALL2820
GIMEMA ALL2820: Intermediate Analysis of Phase III Trial of First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia

Released: December 13, 2024

Expiration: December 12, 2025

Activity

Progress
1
Course Completed